BPA Call 36E79720A0008-36C24121N0566
- This federal contract award is for the delivery of the drug Tyvaso to the U.S. Department of Veterans Affairs (VA). The prime contractor is United Therapeutics Corp, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The contract has a ceiling value of $151,408.29 and is a firm-fixed-price delivery order placed against United Therapeutics' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs. The contract supports the VA's mission...
- This federal contract award is for TYVASO TREPROSTINIL, a pharmaceutical product, awarded to United Therapeutics Corp, a registered small disadvantaged business and manufacturer of pharmaceutical goods. The $31,959.14 firm fixed price delivery order is placed against United Therapeutics' Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) for Pharmaceuticals and Drugs. Additionally, United Therapeutics holds a $50 million VA Blanket Purchase Agreement (BPA) and...
- This federal contract award is for delivery orders of the pharmaceutical product Tyvaso, placed by the U.S. Department of Veterans Affairs (VA) against United Therapeutics Corporation's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs. The contract has a ceiling value of $88,122.38 and a period of performance through September 30, 2019. United Therapeutics, a self-certified small disadvantaged business and for-profit manufacturer, is the prime contractor. The contract does...
- This federal contract award is for the supply of Tyvaso 64 MCG kits by United Therapeutics Corp, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods. The contract has a ceiling value of $16,514.15 and is a firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 5. The contract is placed against United Therapeutics' Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs,...
- This federal contract award to United Therapeutics Corporation is a Delivery Order under the company's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs with the U.S. Department of Veterans Affairs (VA). The contract, valued at $191,017.06, is for the delivery of the pharmaceutical product Tyvaso to the VA's Veterans Integrated Service Network 21. Tyvaso is an inhalation solution used to treat pulmonary arterial hypertension, a condition that disproportionately...
- This is a firm-fixed price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to United Therapeutics Corp, a self-certified small disadvantaged business and manufacturer of specialized pharmaceutical goods. The contract, valued at $379,307.53, is for the delivery of Tyvaso kits and cartridges to the VA. The contract is part of United Therapeutics' Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs, and the company holds a Blanket Purchase...
- This federal contract award is for the delivery of TYVASO 0.6 REFILL KIT pharmaceutical products to the U.S. Department of Veterans Affairs (VA). The contract was awarded to United Therapeutics Corp, a small disadvantaged business and for-profit manufacturer of pharmaceutical goods, primarily focusing on treatments for pulmonary arterial hypertension and certain types of cancer. The contract has a ceiling value of $14,989.01 and is a Firm Fixed Price Delivery Order issued against United...
- This firm fixed price delivery order contract was awarded by the Department of Veterans Affairs (VA) to United Therapeutics Corp, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods. The $100,810.97 contract provides the VA's Veterans Integrated Service Network 21 with Tyvaso inhalation solution and related drugs Remodulin, Orenitram and Unituxin to treat pulmonary arterial hypertension and cancer in veterans. The order was placed against United Therapeutics'...
- The U.S. Department of Veterans Affairs (VA) awarded a $14,693.62 firm-fixed-price delivery order to United Therapeutics Corp, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods, for the TYVASO 0.6 REFILL KIT. This delivery order is placed against United Therapeutics' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs. United Therapeutics has two significant Indefinite Delivery Vehicles (IDVs) with the VA, including a $50 million Blanket...
- This is a federal contract award to United Therapeutics Corporation, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods, by the U.S. Department of Veterans Affairs (VA). The contract is a delivery order under the VA's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs, with a ceiling value of $83,141.19. The contract is for the supply of the drug Tyvaso, an inhalation solution used to treat pulmonary arterial hypertension. This award is not...
- Pharmaceuticals and Drugs (FSS-61-IB)Master GSA Schedule
- 36F79720D0104-36E79720A0008Blanket Purchase Agreement
- 36E79720A0008-36C24121N0566BPA Call
This federal contract award is for the procurement of TYVASO, a pharmaceutical product developed and manufactured by United Therapeutics Corp, a self-certified small disadvantaged business. The contract, worth $13,050.45, was awarded by the Veterans Integrated Service Network 1 (VISN 1), a division of the U.S. Department of Veterans Affairs (VA), to United Therapeutics as the prime contractor. This is a firm fixed-price Blanket Purchase Agreement (BPA) call order placed against United Therapeutics' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs. The contract has an ultimate completion date of May 20, 2021. United Therapeutics is the sole provider for this order, with no set-aside designation applied. The contract is part of a larger $50 million BPA and a $198 million FSS contract held by United Therapeutics, which facilitate the VA's centralized procurement of the company's pulmonary arterial hypertension and oncology drug portfolio, including Orenitram, Remodulin, Tyvaso, and Unituxin.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.1k | 4/19/21 |